Floatz logo

Opakalim

Bipolar Disorder

Biohaven Therapeutics Ltd.Small moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LITHIUM, ELEMENTAL
University of Aarhus
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
CITALOPRAM
University of Texas Southwestern Medical Center
Phase 4BBB
Cipralex
First Affiliated Hospital of Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Opakalim is also rated in:

focal epilepsyDormant
B
Indicative ·
62 / 100
View asset →
generalized epilepsyDormant
B
Indicative ·
57 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →